Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPediatrics/NeonatologyAetna palivizumab (Synagis) Coverage Update | Open…
    Ask Trek AI about this page
    CurrentAetnaPolicy 0318

    Palivizumab (Synagis) prophylaxis for RSV

    Customize your policy alerts

    Sign up for Aetna Policy 0318 alerts

    Get alerted when Policy 0318 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical background, evidence, and guideline-based indications and considerations for use of palivizumab (Synagis) for prevention of serious RSV lower respiratory tract disease in high-risk infants and young children.

    Policy Summary
    PayerAetna
    PolicyPalivizumab (Synagis) prophylaxis for RSV
    Policy CodePolicy 0318
    Change TypeNo material change
    Effective DateApr 1, 1997
    Last ReviewFeb 15, 2024
    Next Review DateJul 25, 2024
    Key ActionObtain prior authorization documenting eligibility per AAP criteria and planned dosing (15 mg/kg IM monthly, up to 5 doses) before administration.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    5max monthly doses recommended for a season
    >24wprotective duration after 5 doses
    58%mean concentration decrease after bypass
    45%RSV hospitalization reduction (CHD trial)
    15 mg/kgintramuscular dose
    04/01/1997policy effective date

    Coverage Criteria for Palivizumab (Synagis)

    Initial season prophylaxis (first year)

    Covered when ALL of the following AAP-based criteria are met for the first year of life (examples summarized from AAP guidance):

    First-year eligibility - gestational age: Infants born before 29 weeks, 0 days' gestation qualify for prophylaxis in the first year of lifegestational age <29w0d

    AAP recommendation (2014; reaffirmed 2019)

    Chronic Lung Disease of Prematurity (first year): Preterm infants born <32 weeks, 0 days who required >21% oxygen for at least 28 days after birth (CLD) qualify in the first year of lifegestational age <32w0d AND >21% O2 >=28 days

    Definition and recommendation from AAP

    Hemodynamically significant CHD: Infants with hemodynamically significant congenital heart disease may be considered for prophylaxis in the first year of life based on physiologic impairment (e.g., medication for CHF, moderate-to-severe pulmonary hypertension, cyanotic defects per cardiology consult)age <=12 months at season onset

    AAP guidance; trial evidence supports reduced hospitalizations

    Dose and timing: Up to 5 monthly doses of palivizumab (15 mg/kg per dose) during the RSV season; start timing based on regional season onset to provide coverage through the peak season<=5 monthly doses per season

    AAP recommends maximum 5 doses; provides >24 weeks protective concentrations for most infants

    Second season (limited) prophylaxis

    Covered in the second year of life only when ALL of the following are met:

    Second-year CLD continuation: Child born <32 weeks, 0 days who required at least 28 days of supplemental oxygen after birth AND continues to require medical support (supplemental oxygen, chronic corticosteroid, or diuretic therapy) within 6 months before the start of the second RSV seasonongoing medical support within 6 months

    AAP recommendation; defines candidates for a second season

    Other second-year indications: Children younger than 24 months who will be profoundly immunocompromised during the RSV season or children with severe chronic lung disease manifestations may be considered for second-season prophylaxisage <24 months for immunocompromised consideration

    Limited, case-by-case AAP guidance

    Populations with limited evidence / discretionary use

    Considered (but not routinely recommended) — clinical discretion required:

    Cystic fibrosis with severe features: Infant with cystic fibrosis who has clinical evidence of chronic lung disease and/or nutritional compromise in the first year may be considered for palivizumab; continued second-year use may be considered for severe lung disease or weight-for-length <10th percentileCF with CLD or nutritional compromise; second-year severe disease criteria

    CF Foundation/AAP statements; evidence limited and additional RCTs needed

    Childhood interstitial lung disease (chILD): Children with severe chronic lung disease who require medical therapy may be considered for prophylaxis (may benefit for up to 2 seasons); effectiveness is uncertain and evidence is limitedcase-by-case clinical severity

    Limited/retrospective data; effectiveness unclear

    Population-specific prophylaxis criteria

    Covered when ALL of the following are met (population-specific summaries from the document):

    Preterm infants: Infants born before 29 weeks, 0 days gestation who are younger than 12 months at the start of RSV season qualify for prophylaxis; preterm infants with CLD (gestational age <32 weeks and oxygen requirement >21% for first 28 days) may qualify in the first year; second-year prophylaxis only if ongoing medical support in prior 6 monthsgestational age and oxygen requirement criteria

    Derived from AAP guidance; infants born during season may require fewer than 5 doses

    Immunocompromised children: Children younger than 24 months who are profoundly immunocompromised during the RSV season may be considered for palivizumab prophylaxisage <24 months and profound immunocompromise

    RCT evidence lacking; AAP recommends consideration on a case-by-case basis

    Cystic fibrosis (CF): Infants with CF who have clinical evidence of chronic lung disease and/or nutritional compromise in the first year may be considered for prophylaxis; continued use in the second year may be considered only for severe lung disease manifestations or weight-for-length <10th percentile

    AAP-based eligibility and dosing

    Covered when ALL of the following are met per AAP recommendations:

    Eligibility and administration: Patient meets an AAP-defined high-risk category (examples: preterm infants <29 weeks gestation and <12 months at season start; infants/children <12 months with hemodynamically significant CHD; preterm infants with CLD as defined; infants with significant airway anomaly or neuromuscular condition impairing secretion clearance; profoundly immunocompromised children <24 months; selected CF patients with severe lung disease or nutritional compromise). Synagis is administered intramuscularly at 15 mg/kg once monthly beginning prior to local season onset.5 monthly doses typical; >5 doses generally not recommended in continental US

    See Appendix A for detailed indications and footnote defining medical support (oxygen, diuretics, chronic corticosteroid)

    Extended dosing during atypical RSV activity

    Programmatic considerations for atypical seasons:

    Atypical season dosing: During atypical interseason RSV activity or regional surges, clinicians may consider providing more than five consecutive doses of palivizumab to eligible children in areas with high activity, or fewer than five doses in areas with limited activity; decisions should be based on regional RSV surveillance and clinical judgmentNo specific numeric threshold; regional RSV activity guides decision

    AAP acknowledges limited data on >5 doses but reports no increased adverse events in available reports

    Palivizumab prophylaxis is not recommended for otherwise healthy infants born at or after 29 weeks, 0 days' gestation. The AAP-based guidance referenced in this policy specifies that infants born before 29 weeks, 0 days gestation who are younger than 12 months at the start of the RSV season are the primary prematurity group for which prophylaxis is recommended; infants born at or after 29 weeks are generally excluded from routine prophylaxis unless other qualifying conditions (e.g., CLD, hemodynamically significant CHD) are present.

    Use of palivizumab to control health care–associated RSV outbreaks is not recommended. Infection control practices (rapid identification, cohorting, and strict hygiene) are the primary measures for outbreak control, and the AAP and this policy state there are no rigorous data to support routine prophylactic use of palivizumab for outbreak containment.

    Routine or universal palivizumab prophylaxis for children with cystic fibrosis is not established. The AAP allows consideration in an infant with CF who has clinical evidence of chronic lung disease or nutritional compromise, but published evidence is limited and systematic reviews conclude that additional randomized studies are needed before recommending routine prophylaxis in CF.

    Under routine circumstances in the continental United States, administration of more than 5 monthly doses of palivizumab is not recommended. Five monthly 15 mg/kg doses were selected to provide trough concentrations above the proposed protective threshold for most infants and to cover the usual RSV season; extended dosing beyond five consecutive monthly doses is reserved for atypical or interseasonal activity and should be based on regional epidemiology and clinical judgment.

    This Clinical Policy Bulletin provides a partial, general description of plan benefits and is intended to assist in administering benefits; it does not constitute a contract, guarantee coverage, or replace the terms of a member's plan. Providers should consult specific plan documents and prior authorization processes for definitive coverage determinations.

    Palivizumab is a prophylactic agent and is not supported as a treatment for active RSV infection. Randomized and systematic evidence has not demonstrated clinical benefit when palivizumab or other immune globulins are used to treat established RSV disease; therefore treatment use is not recommended.

    AAP guidance does not recommend routine second-year prophylaxis based on a history of prematurity alone. Second-season palivizumab may be considered only for infants who meet the specific CLD criteria and continue to require medical support (e.g., supplemental oxygen, chronic corticosteroid or diuretic therapy) in the 6 months before the second RSV season; prematurity without ongoing medical needs is insufficient to justify second-year dosing.

    Antigen-detection assays have important limitations and should not be used alone to define RSV season onset or offset. These assays can overestimate RSV risk at season edges because sensitivity and specificity are low when community prevalence is low, which may result in inappropriate timing of prophylaxis if relied upon without corroborating epidemiologic data.

    Coding and Clinical Metrics

    Clinical trial diagnosis codes referencedICD-9
    No codes listed
    Relevant billing codes (not listed)mixed
    NDC/HCPCS not specifiedDocument lists Synagis dosing and administration but does not provide explicit billing codes in this section.
    Trough serum concentration protective duration
    Protective duration after full regimen>24 weeks of serum palivizumab concentrations after 5 monthly 15 mg/kg doses for most infants
    Typical dosing schedule to achieve durationFive monthly doses beginning prior to local RSV season onset (commonly November start)
    AAP recommendation on additional dosingAdministration of more than 5 monthly doses is not recommended within the continental United States
    Post-cardiopulmonary bypass concentration drop
    Mean post-bypass decreaseMean serum palivizumab concentration decreased by ~58% after cardiopulmonary bypass
    Measured example values

    Provider Actions, Authorization & Documentation

    Prior Authorization

    Obtain prior authorization to verify guideline-based eligibility

    Prior authorization is typically required to confirm that the infant/child meets guideline-based eligibility (e.g., gestational age criteria, chronic lung disease or hemodynamically significant CHD, and appropriate season timing) and that the planned number of doses (usually up to 5 per RSV season) is consistent with recommendations.

    • Confirm gestational age and age at season start (e.g., <29 weeks gestation and <12 months for first-season eligibility).
    • Document qualifying conditions such as CLD, hemodynamically significant CHD, neuromuscular/airway abnormalities, profound immunocompromise, or selected cystic fibrosis criteria.
    • Indicate intended dosing plan (15 mg/kg IM monthly) and number of monthly doses (typically ≤5).
    Documentation Required

    Document medical necessity per AAP criteria

    Provide medical necessity justification demonstrating the patient meets AAP qualifying clinical criteria (for example, prematurity <29 weeks gestation and age <12 months at season start, or CLD defined by gestational age <32 weeks and >21% O2 for ≥28 days).

    Background and Context

    Respiratory syncytial virus causes annual epidemics of bronchiolitis and pneumonia in infants; palivizumab (Synagis) is a humanized monoclonal antibody shown in randomized trials to reduce RSV-related hospitalizations and severity measures in selected high‑risk infants. Protective trough concentrations (a proposed correlate of protection) are achieved with the approved regimen of 15 mg/kg intramuscularly once per month for up to 5 monthly doses, which provides serum levels above the suggested protective threshold for most infants and covers the typical RSV season.

    Definitions and Clinical Terms

    Chronic Lung Disease (CLD) of prematurity
    Gestational age criterionGestational age <32 weeks, 0 days at birth
    Oxygen requirement criterionRequirement for >21% supplemental oxygen for at least the first 28 days after birth
    Definition summaryCLD of prematurity defined as birth <32 wks 0 days plus >21% O2 for ≥28 days
    Hemodynamically significant congenital heart disease (HS-CHD)
    Definition basisCardiac conditions that cause physiologic cardiovascular impairment such as congestive heart failure requiring medication, moderate-to-severe pulmonary hypertension, or cyanotic defects where prophylaxis may be beneficial
    Age contextMost applicable to infants and children younger than 12 months at season onset (some recommendations extend to <24 months post‑transplant), decision based on degree of physiologic compromise
    Policy Summary
    PayerAetna
    PolicyPalivizumab (Synagis) prophylaxis for RSV
    Policy CodePolicy 0318
    Change TypeNo material change
    Effective DateApr 1, 1997
    Last ReviewFeb 15, 2024
    Next Review DateJul 25, 2024
    Key ActionObtain prior authorization documenting eligibility per AAP criteria and planned dosing (15 mg/kg IM monthly, up to 5 doses) before administration.
    SourceLink
    On This Page
    Coverage Criteria for Palivizumab (Synagis)Coding and Clinical MetricsProvider Actions, Authorization & DocumentationBackground and ContextDefinitions and Clinical Terms
    clinical CLD or nutritional compromise; second-year severe disease criteria

    Evidence mixed; systematic reviews call for more RCT data

    Reported paired levels fell from 98 mcg/mL (±52) to 41.4 mcg/mL (±33) after bypass
    Postoperative dosing considerationConsider a postoperative 15 mg/kg palivizumab dose after cardiac bypass or ECMO for children who continue to require prophylaxis
    Palivizumab dosing duration
    Standard seasonal regimenFive monthly intramuscular doses (15 mg/kg each) to cover the typical RSV season
    Timing examplesIf first dose in November, five doses protect through April; if initiated in October, final dose in February; if initiated in December, final dose in April/May
    Clinical trial basisRecommendation derived from IMpact‑RSV and cardiac trials showing adequate troughs after 5 doses
    Protective serum concentration
    Proposed serologic correlateSerum palivizumab concentration ≥30 µg/mL is the proposed protective trough level
    Evidence basisAnimal-model correlate; 5 monthly doses produced troughs ≥30 µg/mL for over 20 weeks in trial subjects
    Clinical implicationTarget trough used to justify standard 5-dose regimen to maintain protective levels through most RSV seasons
    PCR-based season onset threshold
    PCR-based season onset threshold>3% PCR positivity for RSV for the first of 2 consecutive weeks defines season onset
    RationalePCR detects lower weekly percent positives than antigen tests; 3% chosen because summer baseline typically <3% and positivity rises rapidly after threshold
    Comparison to antigen methodAntigen-based season onset traditionally uses >10% positivity; PCR-specific methods capture more detections
    • If claiming CLD, include documentation of gestational age and oxygen requirement for the first 28 days after birth.
    • For second-season requests, document ongoing medical support (supplemental oxygen, chronic corticosteroid, or diuretic therapy) within the 6 months before season start.
    Prior Authorization

    Include AAP-consistent eligibility details with prior authorization

    When requesting authorization for Synagis, include documentation consistent with AAP recommendations: gestational age, presence and definition of CLD, hemodynamically significant CHD details, immunocompromise status, and planned administration (15 mg/kg IM monthly).

    • Specify the AAP-defined high-risk category being claimed (e.g., preterm <29w0d, CLD, HS-CHD, neuromuscular/airway condition, profound immunocompromise <24 months).
    • Include intended dosing: Synagis 15 mg/kg IM once monthly beginning prior to local RSV season onset.
    Note

    Reference Aetna policy portal for prior authorization specifics

    Consult the Aetna policy portal and Clinical Policy Bulletin notes for specific prior authorization processes and any administrative requirements referenced by the policy.

    • Follow Aetna Clinical Policy Bulletin instructions for submission and documentation.
    • Check policy history and additional information pages for updates to prior authorization procedures.
    Step Therapy

    No step‑therapy sequencing; not for treatment of active RSV

    No step-therapy or sequencing requirements are specified; palivizumab is prophylactic and is not used to treat active RSV infection—do not submit authorization requests as treatment for acute RSV disease.

    • Do not use palivizumab as therapy for active RSV; clinical trials and reviews do not support treatment efficacy.
    • No prior requirement to fail other therapies is indicated for prophylactic use.
    Note

    Recognize palivizumab as adjunctive—not primary—therapy in immunocompromised patients

    In immunocompromised patients, established antiviral therapy (e.g., aerosolized ribavirin) and infection-control measures are the primary treatments; palivizumab is considered adjunctive and not a first-line therapy for active infection.

    • For RSV infection in immunocompromised adults/children, aerosolized ribavirin is the preferred backbone of therapy.
    • Palivizumab may be considered adjunctively for prevention in high-risk immunocompromised patients but lacks randomized trial evidence for treatment.
    Step Therapy

    No step therapy requirement specified

    No step therapy requirements are specified in this policy for initiation of palivizumab prophylaxis.

    Step Therapy

    No step therapy requirement (confirmatory)

    (Duplicate) No step therapy requirements are specified in these policy sections.

    Documentation Required

    Document bypass and consider postoperative 15 mg/kg dose

    If the patient undergoes cardiopulmonary bypass and remains eligible for prophylaxis, document the perioperative bypass and consider administering a postoperative dose of palivizumab 15 mg/kg when the child is medically stable.

    • Document occurrence of cardiopulmonary bypass and the indication for continued prophylaxis.
    • Record timing and dose of the postoperative 15 mg/kg palivizumab administration.
    Documentation Required

    Document dosing plan and qualifying conditions for authorization

    Support authorization and dosing requests with documentation showing the intended dosing schedule (typically up to 5 monthly 15 mg/kg doses) and the qualifying clinical condition(s) that meet AAP criteria.

    • Include birth gestational age and age at season start (e.g., <29w0d and <12 months for first-season eligibility).
    • If claiming CLD, provide oxygen requirement history (>21% O2 for ≥28 days) and evidence of ongoing medical support if requesting a second season.
    Billing Rule

    Record Synagis dosing: 15 mg/kg IM monthly starting before season

    Document administration as Synagis intramuscular 15 mg/kg once monthly beginning prior to local RSV season onset; include this dosing plan in authorization requests and medical records.

    • State planned start relative to regional season (e.g., beginning in November in many areas).
    • Indicate the number of monthly doses planned (typically up to 5).
    Documentation Required

    Follow Aetna Clinical Policy Bulletin for documentation resources

    Include policy history and Clinical Policy Bulletin resources when preparing documentation; follow Aetna Clinical Policy Bulletin notes and definitions for submission and record-keeping.

    • Use the Clinical Policy Bulletin as a guide for documentation requirements but consult the policy portal for full administrative details.
    • Keep records of policy versions and review dates cited in submissions.
    Denial Risk

    Limit routine dosing to a maximum of 5 monthly doses per season

    Do not request more than five monthly doses for routine prophylaxis within the continental United States; administration beyond 5 monthly doses in a season is generally not recommended except in exceptional atypical interseason situations.

    • AAP guidance states 5 monthly doses provide >24 weeks of protective concentrations for most infants.
    • Consider extended dosing only during atypical regional interseason RSV activity and document regional surveillance supporting the decision.
    Denial Risk

    Palivizumab is not recommended for outbreak control in health‑care settings

    Do not rely on palivizumab for control of health care–associated RSV outbreaks; emphasize strict infection‑control measures instead and be aware that requests citing outbreak control without qualifying clinical indications may not be supported.

    • Primary emphasis for outbreak control should be infection control and cohorting of infected infants.
    • AAP states palivizumab use is not recommended to control health care–associated RSV outbreaks due to lack of rigorous supporting data.
    Denial Risk

    Do not rely solely on antigen assays to define RSV season timing

    Avoid using antigen-detection assay results alone to define RSV season onset/offset for prophylaxis decisions or authorization timing, because antigen assays may overestimate risk at season edges; prefer PCR-based thresholds or local surveillance data when available.

    • Antigen-detection assays have low sensitivity/specificity at season onset and end and may yield high false-positive rates when prevalence is low.
    • Consider PCR-based definitions (e.g., >3% RSV-positive for the first of two consecutive weeks) or state/local surveillance to determine season timing.
    Note
    ExclusionsHemodynamically insignificant lesions and adequately corrected lesions (unless ongoing medication for CHF) generally are not candidates
    Protective trough level
    Protective trough level (repeat)Proposed serologic correlate is a serum palivizumab concentration ≥30 µg/mL
    Trial observationFive monthly doses resulted in trough concentrations ≥30 µg/mL for over 20 weeks in most subjects
    Use in dosing rationaleThis threshold underpins the recommendation for a 5-dose seasonal regimen to maintain protection
    Chronic lung disease (CLD) duplicate definition
    Gestational age criterion (duplicate)Gestational age <32 weeks, 0 days at birth
    Oxygen requirement (duplicate)Requirement for >21% supplemental oxygen for at least the first 28 days after birth
    Context for prophylaxisPreterm infants meeting this CLD definition may qualify for palivizumab in the first year; second‑year prophylaxis only if ongoing medical support in prior 6 months
    Chronic lung disease (CLD) prophylaxis definition variant
    Prophylaxis-specific CLD definitionFor prophylaxis, CLD of prematurity = gestational age <32 weeks, 0 days AND requirement for >21% oxygen for at least the first 28 days after birth
    Second-season requirementFor second RSV season, prophylaxis considered only if continued need for medical support (supplemental oxygen, chronic corticosteroid, or diuretic therapy) within 6 months before season start
    ImplicationChildren with CLD who do not continue to require medical support in second year are not recommended to receive prophylaxis
    Hemodynamically significant congenital heart disease (CHD)
    Age and medication requirementInfants and children <12 months with CHD who are acyanotic and receiving medications to control congestive heart failure or who will require cardiac surgery are candidates for prophylaxis
    Other qualifying CHD featuresIncludes infants with moderate to severe pulmonary hypertension and selected cyanotic defects after cardiology consultation
    Postoperative and transplant noteChildren <24 months who undergo cardiac transplantation during RSV season may be considered for palivizumab; consider postoperative dosing after bypass if still eligible